Washington, DC, Sept. 6-7, 2019
Application deadine: Dec. 15, 2018

When the French pharmaceutical company Roussell Uclaff, a subsidiary of the German chemical giant Hoechst AG, was ready to introduce an abortion pill in 1988, American activists flooded the company’s headquarters near Frankfurt with protest letters. In response, the company’s German CEO mandated to stop the project. But the French state, a Hoechst minority shareholder, took the idea across the border, patented it, and embarked on medical trials for the new product in France. Ten years later, scientists in the United States successfully isolated human embryonic stem cells. The country’s regulatory framework had left them free to let the cells proliferate indefinitely. But researchers adopted concepts implemented in Britain to limit the cells’ growth to 13 days after gestation. Continue reading→